PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Bromocriptine”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,171 records · Page 65Linked to original sources

[Benign angiopathy of the puerperium: a clinicoradiological case associated with ingestion of bromocriptine].

We report a case of benign cerebral angiopathy in a 37 year-old woman in the postpartum period occurring after bromocriptine therapy to suppress lactation. She presented with severe headache, hyperthermia and bradycardia. She had partial seizure. Angiography excluded cortical vein thrombosis but revealed multiple narrowing of intracerebral arteries. Bromocriptine was stopped. The patient totally recovered. A second angiography performed 3 months later was normal. Postpartum cerebral angiopathy is considered as rare but the prevalence is probably underestimated. Neurological features of this affection are multiple. Diagnosis is made by angiography performed in emergency and which showed narrowing of intracerebral arteries which are reversible. Prognosis is good. Reversible vasoconstriction may be due to acute arterial hypertension, sometimes triggered by ergot derivatives.

Adult↗

The dopamine D2 receptor agonists, quinpirole and bromocriptine produce conditioned place preferences.

1. The conditioned place preference paradigm was used to examine the role of the D2 receptor in mediating the reinforcing effects of dopamine (DA) agonists. 2. During the 3-day pre-exposure phase, rats explored two distinctive end compartments which were adjoined by a small tunnel. During the 8-day conditioning phase, groups of rats were treated with the selective D2 receptor agonists, quinpirole (0.01, 0.025, 0.05, 0.10, 0.25, 1.0 and 5.0 mg/kg IP) or bromocriptine (0, 0.01, 0.1, 0.5, 1.0, 5.0 and 10.0 mg/kg IP) and confined to one compartment for 30 min. On alternate days, rats received vehicle injections and were placed in the opposite compartment. Test days occurred over the remaining 3 days during which untreated animals explored both compartments. 3. Rats conditioned with quinpirole or bromocriptine showed significant increases in time spent in the drug-paired environment from pre-exposure to test indicating the establishment of conditioned place preferences. 4. This suggests a functional role for the D2 receptor in mediating the rewarding effects of DA agonists.

Animals↗

Effects of prolactin and bromocriptine in Discoglossus pictus (anuran amphibian. Otth) tadpoles.

1. The results obtained by ovine prolactin administration during the larval development of Discoglossus pictus (OTT) suggests that prolactin-like hormone is the "larval factor" necessary for growth and for maintaining the larval aquatic features. 2. Bromocriptine treatment during the larval development of D. pictus has contrary effect on growth and larval structures. 3. Prolactin administration does not inhibit but delays metamorphosis. 4. When bromocriptine is added at late stages of the development, metamorphosis is accelerated.

Animals↗

Bromocriptine and lisuride stimulate the accumulation of cyclic AMP in intact slices but not in homogenates of rat neostriatum.

The effects of bromocriptine and lisuride on cyclic AMP concentrations in homogenates and in intact slices of rat neostriatum were investigated. Significant increases in cyclic AMP concentration were found after a 10-min exposure to bromocriptine and lisuride in striatal intact slices. On the contrary, as previously found, the two dopaminergic ergot derivatives did not stimulate dopamine-senstiive adenylate cyclase present in striatal homogenates. The stimulatory effects observed only in intact tissues were blocked by the specific dopamine receptor blocking agent fluphenazine. It is tempting to conclude that dopaminergic ergot derivatives have a site of action different from that stimulated by classic dopamine agonists in tissue homogenates.

Animals↗

Bromocriptine-induced hypothermia in Balb/C mice: its possible mechanism of action.

1. Administration of bromocriptine (0.1-2.5 mg/kg, i.p.) to mice produced hypothermia. 2. Pretreatment with the alpha 1-adrenoceptor blocker, prazosin (2.0 mg/kg, i.p.) or the alpha 2-adrenoceptor antagonist yohimbine (2.5 mg/kg, i.p.) had no effect on this response. 3. The inhibitor of catecholamine synthesis, alpha-methyl-p-tyrosine, and the muscarinic antagonist, atropine (10 mg/kg, i.p.) failed to alter the hypothermia. 4. Pretreatment with the dopamine (DA) receptor antagonists haloperidol (0.02 mg/kg, i.p.) or cis-flupenthixol (0.01 mg/kg, i.p.) completely blocked this response while trans-flupenthixol (0.05 mg/kg, i.p.) was inactive. 5. Depletion of 5-HT in the brain by p-chlorophenylalanine reduced the hypothermic response. 6. Similarly, pretreatment with the serotonergic (5-HT) receptor blocker ketanserin (1 mg/kg, i.p.) attenuated the hypothermia and at a dose of 2 mg/kg (i.p.) it completely blocked the hypothermic response. 7. Methysergide (5 mg/kg, i.p.) was also effective in antagonizing the hypothermia. 8. It was concluded that both DA and 5-HT mechanisms are involved in bromocriptine-induced hypothermia in mice.

Acetylcholine↗

Lack of effect of bromocriptine and domperidone on arginine-vasopressin response to insulin-induced hypoglycemia in normal men.

In order to establish whether the arginine-vasopressin (AVP) increase evoked by insulin-induced hypoglycemia is mediated by a dopaminergic pathway, 16 normal men were given an insulin tolerance test (ITT) under basal conditions and after treatment with the dopamine agonist bromocriptine (2.5 mg by mouth) (eight subjects) or the dopamine antagonist domperidone (10 mg i.v.) (eight subjects). In addition, five out of eight subjects in each group were treated with higher doses of bromocriptine (5 mg by mouth) or domperidone (20 mg i.v.). Basal and ITT-stimulated AVP secretion was not modified by the drug treatments, suggesting that dopamine is not involved in the regulation of AVP secretion in response to insulin-induced hypoglycemia.

Adult↗

Effects of bromocriptine on the voluntary consumption of ethanol, water, and solid food by UChA and UChB rats.

The effect of bromocriptine (stimulant of dopaminergic D2 receptors) on the daily consumption of 10% v/v ethanol solution, distilled water, and solid food, under free-choice conditions, was measured in nine genetically low (UChA) and six high ethanol consumer (UChB) adult female rats. Animals were housed in individual cages and maintained at room temperature of 23 +/- 1 degree C and with 12/12 h dark/light rhythm. The consumption of ethanol solution, water, and solid food was measured in pretreatment, treatment, and posttreatment periods of 3 days (Tuesday through Thursday) of 3 consecutive weeks. During the treatment period rats received daily a single oral dose of 8 mg of bromocriptine mesylate (Sandoz) suspended in 1 ml of water per kg of body weight. Data analysis was performed with a method previously reported, which allows to recognize specific effect of ethanol intake, depurated from the effects on calories and/or water consumption. Results showed that all UChB rats decreased significantly and specifically the consumption of ethanol solution during the treatment period compared to the pretreatment period (mean: -58 +/- 15%) and recovered the pretreatment consumption in the posttreatment period, without significant changes in the consumption of food and/or total water. The only significant change observed in UChA rats was a decrease of the consumption of solid food (mean: -15 +/- 5%). Results are consistent with the idea that a dopaminergic D2 synapsis participates in the neural network responsible for satiation with ethanol.

Alcohol Drinking↗

Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse.

Bromocriptin (BCT) is a dopaminergic receptor agonist, poorly transported through the blood-brain barrier (BBB) and responsible for central side effects. Interactions between BCT and the efflux protein, P-glycoprotein (Pgp), have been described in vitro but nothing is known in vivo nor at the BBB level. At the BBB, in vivo, we investigated BCT as (i) a Pgp substrate by comparing the brain uptake in CF1 mdr1a(-/-) and mdr1a(+/+) mice with or without inhibitors of Pgp (valspodar, elacridar); (ii) a Pgp inducer by looking at the effect of repeated doses of BCT on cerebral uptake of digoxin and comparing it to the effect of dexamethasone and rifampicin; (iii) a Pgp inhibitor by determining the effect of a single dose of BCT on cerebral uptake of digoxin and comparing it to the effect of valspodar. CF1 mdr1a(-/-) mice showed much higher brain uptake of BCT than CF1 mdr1a(+/+) mice and brain uptake of BCT was higher in CF1 mdr1a(+/+) mice pre-treated with valspodar or elacridar indicating that BCT is a Pgp substrate at the BBB level. Brain uptake of digoxin was not modified in CF1 mdr1a(+/+) mice pre-treated with a single dose or repeated doses of BCT, indicating that BCT is neither a Pgp inductor nor a Pgp inhibitor at the BBB in the chosen experimental setting. In vivo, at the mouse BBB level and in our experimental conditions, bromocriptin is a Pgp substrate but is not a Pgp modulator.

ATP Binding Cassette Transporter, Subfamily B↗

Twin gestation induced by clomiphene citrate and bromocriptine in both horns of a bicornuate uterus.

OBJECTIVE: To describe a case of twin gestation that occurred in both horns of a bicornuate uterus after the administration of clomiphene citrate and bromocriptine. DESIGN: Case report. SETTING: Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Korea. PATIENT(S): A 34-year-old woman presented with secondary infertility and hyperprolactinemia. INTERVENTION(S): Bromocriptine, 2.5 mg/day, was administered immediately, and clomiphene citrate, 150 mg/day, was started from menstruation day 5 for 5 days. MAIN OUTCOME MEASURE(S): The establishment of pregnancy and obstetric outcome. RESULT(S): A nonidentical twin pregnancy occurred but ended in preterm delivery at 24 weeks. One baby has survived for over 3 months. CONCLUSION(S): Twin gestation can occur in both horns of a bicornuate uterus after clomiphene citrate administration.

Adult↗

Imaging gene-substance interactions: the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward.

Dopamine is known as the main neurotransmitter modulating the activation of the reward system of the brain. The DRD2 TaqIA polymorphism is associated with dopamine D2 receptor density which plays an important role in the context of reward. Persons carrying an A1 allele have a lower D2 receptor density and a higher risk to show substance abuse. The present study was designed to investigate the influence of the DRD2 TaqIA polymorphism and the selective D2 receptor agonist bromociptine on the activation of the reward system by means of functional magnetic resonance imaging (fMRI). In a double-blind crossover study with 24 participants we found an increase of reward system activation from placebo to bromocriptine only in subjects carrying the A1 allele. Furthermore, only A1 carrier showed an increase of performance under bromocriptine. The results are interpreted as reflecting a specific sensitivity for dopamine agonists in persons carrying an A1 allele and may complement actual data and theories of the development of addiction disorders postulating a higher genetic risk for substance abuse in carrier of the A1 allele.

Adolescent↗

Regression of pituitary microadenoma during and following bromocriptine therapy: persistent defect in prolactin regulation before and throughout pregnancy.

During 5 years of clinical, endocrinologic, and radiologic observations in a woman with a microprolactinoma treated medically with bromocriptine for 29 months, serial hypothalamic-pituitary studies revealed a defect in lactotrope function after prolactin (PRL) concentrations and ovulation were restored to normal. This defect persisted throughout a spontaneously conceived pregnancy in which the PRL, estradiol, and progesterone levels were subnormal, while, the dehydroepiandrosterone sulfate levels were normal and estriol concentrations were elevated. Levels of the beta subunit of human chorionic gonadotropin (hCG) were close to and slightly above the normal ranges. These observations are consistent with a role for PRL, interacting with hCG, in the control of estrogen and progesterone secretion by the fetoplacental unit. Lactation was initiated and maintained post partum. Pituitary function and PrL responses to suckling suggested improved lactotrope function 22 to 25 months after withdrawal of bromocriptine. The impaired lactotrope function, therefore, did not preclude normal implantation, pregnancy maintenance, onset of parturition, fetal development, and lactation.

Adenoma↗

Assessment by computed tomography of the response of pituitary macroadenomas to bromocriptine.

Eleven patients with large pituitary tumours and with extrasellar extension were studied prospectively to assess the response of these tumours to bromocriptine. Five out of the six patients with high serum prolactin due to prolactinomas showed rapid and dramatic reduction in tumour size when treated with bromocriptine. In contrast, none of the five patients with non-functioning tumours showed any change in tumour size on computed tomography.

Adenoma↗

Regression of a prolactin-secreting pituitary tumor during long-term treatment with bromocriptine.

A nulliparous woman with 12 years of amenorrhea, galactorrhea, and hyperprolactinemia and radiologic evidence of a pituitary macroadenoma was treated with large doses of bromocriptine. During treatment the greatly increased prolactin levels normalized and ovulatory menstrual cycles were regained after 48 weeks of treatment. A transsphenoidal surgical exploration of the pituitary fossa was performed after 27 months of treatment. The findings at surgery suggested that regression of the pituitary adenoma had occurred during the prolonged treatment with bromocriptine. After discontinuation of the therapy, the patient continued to ovulate and subsequently conceived.

Adenoma↗

The incidence of complications during pregnancy after treatment of hyperprolactinemia with bromocriptine in patients with radiologically evident pituitary tumors.

The course of pregnancy achieved after bromocriptine therapy is described in nine patients with radiologically evident prolactin-secreting pituitary tumors. In six patients no complications occurred. No changes in sellar size or secondary endocrine deficiencies developed. In three patients, however, complications developed between the 22nd and 24th weeks of pregnancy. Despite prior external pituitary irradiation, one patient developed transient bitemporal hemianopsia and one patient had apoplexy of the pituitary tumor with transient paresis of the left abducens nerve. A third patient developed parasellar expansion of the pituitary tumor with bone destruction and paresis of the right abducens and oculomotor nerves. After transsphenoidal surgery the paresis of both nerves disappeared. Microscopically, the tissue removed at surgery was a chromophobe adenoma with focal fibrosis and calcifications without recent hemorrhages. In the course of more than 100 pregnancies achieved in The Netherlands after bromocriptine therapy, five patients reportedly developed complications of the pituitary tumor. At present, patients in whom complications can be expected cannot be predicted by the size or configuration of the sella turicica or the magnitude of elevation of the plasma prolactin level. In two patients external pituitary irradiation did not prevent complications during pregnancy.

Adult↗

Clinical evaluation of the effects of combined treatment with bromocriptine and spironolactone in two women with the polycystic ovary syndrome.

Two women with the polycystic ovary syndrome were treated with bromocriptine (15 to 20 mg/day) in combination with spironolactone (100 mg/day). In the first woman the combined therapy induced a marked reduction of hirsutism, with ensuing ovulation and pregnancy. In the second woman, who had hyperthecosis and had been refractory to treatment with clomiphene and wedge resection, the combined therapy resulted in abolition of hirsutism, normalization of blood pressure, weight reduction, and improvement in glucose intolerance. In this patient fertility could not be established by the above treatment, but the symptomatic amelioration was so great that she accepted no further attempt to induce ovulation. In view of the marked amelioration of the polycystic ovary syndrome induced by combined bromocriptine and spironolactone treatment, this mode of therapy should receive further consideration.

Adult↗

Rapid regression of a suprasellar extending prolactinoma after bromocriptine treatment during pregnancy.

A patient is described with hyperprolactinemia, post-pill amenorrhea, galactorrhea, and a normal pituitary fossa. Pregnancy occurred after induction of ovulation with bromocriptine. During pregnancy rapidly increasing visual field defects due to suprasellar extension of a pituitary tumor were observed. Operation was advised but refused. The patient was treated with bromocriptine in a dose of 15 mg daily, which resulted in normalization of the bitemporal hemianopia within 2 weeks.

Adult↗

Bromocriptine reduction of prolactinoma size.

Eight consecutive patients with large prolactinomas, as assessed by elevated serum prolactin concentrations and suprasellar extension of the visualized pituitary adenoma on computerized tomographic (CT) scanning, were treated with bromocriptine. With prospective evaluation all eight patients demonstrated disappearance of symptoms ascribed to both the hyperprolactinemia and the tumor itself, and all eight showed a decrease in tumor size within 3 months, as assessed by CT scanning. This prospective study demonstrates that the reduction in size of a large prolactinoma by bromocriptine is commonly observed and should be considered as an initial form of therapy for such patients.

Adenoma↗

Exaggerated prolactin response of thyrotropin-releasing hormone in women with anovulatory cycles: possible role of endogenous estrogens and effect of bromocriptine.

Twenty-one women 18 to 36 years old, presenting with chronic anovulation, were compared with 10 normally cycling women. The patients were characterized by low progesterone (P) levels (0.93 +/- 0.14 ng/ml versus 15.5 +/- 1.4 in controls), whereas 17 beta-estradiol (E2) was moderately decreased (110.2 +/- 8.3 pg/ml versus 162.8 +/- 14.5 in controls) realizing a relative hyperestrogenism. Basal prolactin (PRL) levels were not elevated (12.1 +/- 0.97 ng/ml versus 9.2 +/- 0.7 in controls), but after thyrotropin-releasing hormone (TRH) stimulation an exaggerated response was observed (114.5 +/- 7 ng/ml versus 55.8 +/- 9 in controls). Patients were treated with bromocriptine (1.25 mg 2 times a day) for 3 months. Fifteen responded with ovulatory cycles, and five became pregnant. Progesterone increased significantly (10.2 +/- 1.3 ng/ml), whereas in patients who did not ovulate P increased only slightly (1.56 +/- 0.18 ng/ml). The particular endocrine profile of these patients (P/E2 imbalance) realizing relative hyperestrogenism may be responsible for the exaggerated PRL response to TRH. Bromocriptine, in reducing this transient, or masked, hyperprolactinemia, allows in many patients the return to ovulatory cycles. This mechanism may be one of the possible pathways leading to chronic functional or organic hyperprolactinemia.

Adolescent↗